Rationale There is strong evidence for a dose-response relationship between physical therapy early after stroke and recovery of function. The optimal method of maximizing physical therapy within finite health care resources is unknown. Aims To determine the effectiveness and cost-effectiveness of two alternative models of physical therapy service delivery (seven-days per week therapy services or group circuit class therapy over five-days a week) to usual care for people receiving inpatient rehabilitation after stroke. Design Multicenter, three-armed randomized controlled trial with blinded assessment of outcomes. Study A total of 282 people admitted to inpatient rehabilitation facilities after stroke with an admission functional independence measure (FIM) score within the moderate range (total 40-80 points or motor 38-62 points) will be randomized to receive one of three interventions: usual care therapy over five-days a week standard care therapy over seven-days a week, or group circuit class therapy over five-days a week. Participants will receive the allocated intervention for the length of their hospital stay. Analysis will be by intention-to-treat. Outcomes The primary outcome measure is walking ability (six-minute walk test) at four-week postintervention with three-and six-month follow-up. Economic analysis will include a costing analysis based on length of hospital stay and staffing/resource costs and a cost-utility analysis (incremental quality of life per incremental cost, relative to usual care). Secondary outcomes include walking speed and independence, ability to perform activities of daily living, arm function, quality of life and participant satisfaction.
Introduction
Following a stroke, getting enough physical activity-based therapy is essential to promote recovery of functional abilities (1) and to maintain cardiovascular and metabolic health (2) . Despite this knowledge, studies around the world show that people receiving rehabilitation services after stroke spend very little time engaged in physical activity (3) (4) (5) . Provision of rehabilitation services is expensive; it is therefore vital that novel methods of providing a greater amount of activity-based therapy are investigated for both effectiveness in terms of functional recovery, cost to service providers and cost-effectiveness. Circuit class therapy (CCT) -where people receive activity-based therapy in groups of up to six participants supervised by one to two staff members -has been shown to be a highly effective means of providing a greater amount of therapy time to people receiving inpatient stroke rehabilitation compared with traditional therapy, and has the potential to be a cheaper and more cost-effective option (6) . While there is strong evidence supporting the effectiveness of CCT for improving walking ability in people later after stroke (7) ; the effectiveness of this approach in inpatient rehabilitation facilities has yet to be established. In Australia, many rehabilitation centers are moving toward a seven-days a week model of therapy delivery to maximize therapy time (increase dosage), despite the lack of evidence of the effectiveness of this approach (8) and likely increase in costs involved. It is still unclear whether increased therapy delivered during the week will be more cost effective than therapy delivered across seven-days or whether either the clinical outcomes of such approaches will justify the additional resources required.
The aim of the CIRCIT (Circuit class therapy for Increasing Rehabilitation Intensity of Therapy after stroke) trial is to compare the effectiveness, costs and cost-effectiveness of different models of delivering a greater dosage of activity-based therapy to people after stroke. Our primary hypotheses are:
providing CCT (five-days a week) will lead to improved walking ability compared with usual care therapy (five-days a week)
providing seven-days per week therapy will lead to improved walking ability compared with usual care therapy, and providing CCT (five-days a week) will lead to improved walking ability compared with seven-day week therapy.
Our secondary hypothesis is that CCT will be cheaper and more cost-effective than seven-day week therapy. Further hypotheses relate to the impact of CCT and seven-day week therapy on the ability to perform activities of daily living (ADLs), arm function, quality of life and length of hospital stay.
Study design
CIRCIT is a three-armed, multicenter pragmatic randomized controlled trial with blinded assessment of outcomes and sixmonth follow-up. Within one-week of admission to a rehabilitation facility (or one-month after stroke onset), participants will be randomly allocated to receive one of three methods of physiotherapy service delivery: usual care therapy seven-days per week therapy CCT. Participants will receive the allocated form of physiotherapy service delivery from the day after randomization and for the duration of their stay in the rehabilitation facility. Therapy provided after discharge will be monitored, but not standardized. The trial will be run in at least six rehabilitation facilities in two Australian states. Figure 1 demonstrates the trial flow.
Ethics
Ethical approval has been received from the Human Research Ethics Committees of Flinders Medical Centre, Royal Adelaide Hospital and The Queen Elizabeth Hospital covering all recruitment sites in South Australia. Before the trial commencing at additional sites, all appropriate ethical approval will be obtained.
Patient population: inclusion and exclusion criteria
People admitted to a participating rehabilitation facility with a diagnosis of stroke (hemorrhagic or infarct) with an FIM total score of between 40 and 80 points or motor subscale score of between 38 and 62 points will be invited to participate. Stroke survivors with moderate disability (defined by these FIM score ranges) show the greatest degree of functional recovery (9) and are most likely to benefit from increasing the dose of activitybased therapy. People who were not able to walk independently before their stroke for any reason will be excluded (prior use of a walking aid is acceptable). Participants will provide informed consent or proxy-consent will be sought from the appropriate third party as required.
Baseline measures
The blinded assessor will collect baseline measures within oneweek of admission to rehabilitation. Data to be collected will include demographic details (age, gender), previous function (walking ability, co-morbidities, living arrangements), date of stroke, date of admission to rehabilitation, stroke classification (Oxfordshire Stroke Classification) and details (imaging results, side of stroke, first or recurrent event), visual fields assessment, Mini-mental State Examination, ability to perform ADLs (FIM), walking ability (six-minute walk test (6 minWT), walking speed, Functional Ambulation Classification (FAC)) and arm function (Wolf Motor Function Test (WMFT)). See Table 1 for the schedule of assessment procedures.
Randomization
Participants who meet the inclusion criteria and consent to take part in the trial will be randomized on a one to one basis, stratified by hospital site to receive either five-days a week therapy, five-days a week CCT or seven-days a week therapy. The randomization schedule was computer-generated.
Following the baseline assessment, the on-site investigator will call a central phone-in service, answered by a person independent to the study, to obtain group allocation. This person is the only one with access to the allocation schedule and she has no other role in the trial.
Intervention
The comparison of interest in this trial is mode and intensity of physical therapy delivery, as opposed to content of therapy. The key differences between the intervention arms of the trial are:
total therapy time per week and whether sessions are delivered on an individual basis or in a group setting. The content of therapy sessions will be similar. In all therapy sessions exercises will be progressed according to standard practice, including by increasing number of repetitions, weights, duration of practice and increasing complexity of tasks.
Usual care therapy
Participants randomized to receive usual care therapy will receive all physical therapy according to local site standard practice. This may include individual therapy sessions, hydrotherapy (with a one therapist to one patient ratio) and group therapy as long as this is part of usual care. The total duration of usual care therapy will be no more than 90 min per day, fivedays a week (450 min per week).
Seven-days per week therapy
Participants randomized to receive seven-days a week therapy will receive physical therapy on both Saturday and Sunday for the duration of their inpatient stay, as well as the usual fivedays of the working week. The duration of therapy sessions provided on the weekend will be matched to that provided during the preceding week. The total duration of seven-days a week therapy will be no more than 90 min, seven-days a week (630 min per week).
CCT
This trial aims to assess an alternative model of providing physical therapy to people receiving rehabilitation poststroke. Thus, participants randomized to the CCT arm of the trial will receive CCT as an alternative to usual care; i.e. CCT sessions will replace all other physiotherapy sessions. Participants will receive CCT for up to three-hours per day, usually in two 90-min sessions morning and afternoon. The CCT will involve groups of at least three (ideally four to six) participants and will be staffed by both qualified (physiotherapists) and unqualified staff (therapy assistants and physiotherapy students) with no more than one staff member per three participants. If there are less than three trial participants allocated to the CCT group at any one time, the CCT group will be augmented with nontrial patients with mobility issues. According to the best evidence (10, 11) , exercises included in the CCT sessions will be task-specific, largely activity-focused All people admitted to participating rehabilitation centers with a diagnosis of stroke will be assessed for eligibility Potential participants included if they: -are able to walk independently prior to their stroke -have a FIM total score of 40-80 points or motor score of 38-62 points Protocols (as opposed to impairment-focused) with an emphasis on repetition and feedback. For each participant, exercises will be individually prescribed and progressed in terms of both complexity and intensity (number of repetitions, resistance and duration). Therapy will be aimed at improving mobility as well as (where appropriate) use of the hemiparetic arm. Therapists providing CCT will be pretrained and will be provided with ongoing support and advice as well as a written manual. For a more complete description of the content of CCT please refer to appendix 1 in English et al. (6) . The total duration of CCT will be up to 180 min per day, five-days a week (900 min per week).
The integrity of interventions delivered at each site will be monitored by prospective collection of data regarding therapy time and content, which will be regularly reviewed, as well as a system of regular onsite audits.
Primary outcomes
The primary outcome measure is walking ability as measured by the 6 minWT at four-weeks after randomization. The 6 minWT was chosen as current evidence suggests that the greatest benefit of CCT is in improving walking capacity (7) and this test measures a construct that is meaningful to people with stroke. The four-week time point for the primary outcome measure was chosen to be commensurate with the average length of hospital stay for rehabilitation (12) and because there is evidence for the effectiveness of a four-week package of CCT intervention delivered in addition to usual care therapy in the subacute rehabilitation setting (13) .
Secondary outcomes
Secondary outcomes will provide a broader picture of functional ability and economic implications. They are:
Functional walking ability as measured by the FAC (14), walking speed and the Stroke Impact Scale (15) .
Ability to perform ADLs as measured by the FIM (16) . Arm function as measured by the WMFT (17) .
Quality of life as measured by the Assessment of Quality of Life (AQoL) instrument (18) . Data from the AQoL will also be used for the economic analyses.
Participant satisfaction as measured by the Hopsat questionnaire (19) .
Complications, including adverse events will be monitored for all trial participants. These may include (but are not limited to) worsening of stroke symptoms, falls (including those not resulting in injury), angina or myocardial infarction.
Resource utilization including costs involved with therapy provision (therapist time, therapy equipment, essential discharge equipment such as walking aids).
Length of hospital stay (LOS) as measured by the number of overnight stays in the rehabilitation facility. External barriers to discharge (waiting for essential home modifications or placement in residential care facility) will be documented. All primary and secondary outcome measures (except participant satisfaction) will be administered by the blinded assessor at baseline, two-and four-weeks (7 two-days) after randomization and at three-and six-months (7 one-week) after randomization. To avoid the risk of unblinding, the participant satisfaction questionnaire will be administered by a local therapist, not directly involved in the participant's therapy.
Data monitoring body
The trial will be overseen by a Steering Committee consisting of all members of the investigating team including onsite therapy staff. A Data Safety Monitor who is independent of the trial will review unblinded data with regards to all adverse events and complications regularly and will advise the Steering Committee if safety issues arise.
Sample size
Sample size estimates were based on the ability to detect a between group difference of 116 m in the 6 minWT (standard deviation of 112 m) between the CCT and usual care arms of the trial (13) . In the absence of published data regarding the effect of seven-day week therapy and considering the doseresponse relationship between therapy time and outcome (1) we conservatively estimate the change in the seven-day week therapy arm will be half of that being observed in the CCTarm. Based on two-sided independent t-tests with Type I error set at 0Á025 to allow for multiple testing, a sample size of 75 per arm will provide at least 80% power to test for differences between CCTand usual care, seven-day therapy and usual care and CCT and seven-day therapy. Allowing for a 20% drop out rate, we aim to recruit 282 participants.
Planned statistical analyses
Reporting will follow the CONSORT statement for pragmatic randomized controlled trials.
Baseline characteristics of patients in the three treatment arms will first be described using means and SEMs for continuous variables (or nonparametric equivalent) and counts and percentages for categorical variables. The treatment arms will be examined for comparability at baseline with respect to demographic and prognostic factors. An intention-to-treat analysis will be performed. One-way analysis of variance (ANOVA) with a Sidak post hoc procedure will be used to test for between group differences on the primary and secondary outcomes at four-weeks. Should the outcome measures prove to be not normally distributed, either a transformation will be attempted, or a Kruskal-Wallis H-test will be used followed by post hoc comparisons. Changes in outcome measures over time will be explored using linear mixed effects models. As the sample size will be relatively small, testing for confounding will be undertaken using the change in coefficient method and adjusted analyses undertaken when required.
Economic evaluation
The economic analysis will involve: simple comparison of the mean cost of therapy which will include personnel costs of therapists and therapy assistants (therapy and planning time) mean length of hospital stay, and incremental cost per differential change in patient outcome (as described above) for seven-days a week therapy vs. usual care (five-days a week therapy)
CCT vs. usual care, and CCT vs. seven-days a week therapy. Costs of therapy will include the time to deliver physiotherapy services to the participants (personnel costs) including costs for organization of sessions (prospectively collected), equipment cost and hospital stay, costed at published per diem or diagnostic-related group rates). Interpretation of results will consider both the functional outcomes and differences in costs between the three arms of the trial.
Study organization and funding
Administration and data management activities will be conducted through the International Centre of Allied Health Evidence at the University of South Australia. This trial is funded by the National Health and Medical Research Council of Australia (grant number 631904) and is registered with the Australian and New Zealand Trial Registry (ACTRN12610000096055).
Recruitment
Recruitment to the trial commenced in July 2010. By February 2011, 44 participants had been randomized to the trial.
Summary
Currently CCT is being used in various ways in rehabilitation settings around Australia without clear evidence of its effectiveness. Similarly, many Australian rehabilitation centers have, or are considering implementing weekend therapy services at a significant additional cost to the health care system, without clear evidence of the effectiveness or costeffectiveness of such a service. This trial will be the first to provide rigorous evidence on the effectiveness, cost and costeffectiveness of both CCTand seven-days per week therapy for stroke survivors receiving inpatient rehabilitation, relative to usual care. Improved functional outcomes for people poststroke has significant health and welfare implications for both the individuals, their significant others and the community sector. In addition to the potential to improve functional outcomes, CCT has the potential to lead to reduced LOS (6, 7, 13) which could 'free up' hospital beds for other patients. In 2006, there were 5205 stroke patients discharged from rehabilitation facilities in Australia (20) . If 50% of these were eligible for CCT, even a modest reduction in LOS would release several thousand bed-days for alternative use.
With the aging population and the rising incidence of stroke, the outcome of this trial has the potential to benefit a large section of the population, both in Australia and internationally. If our results are positive in favor of either CCTand/ or seven-days a week therapy, we will have scientific evidence to support changes to the provision of therapy in rehabilitation units. If the results do not support either approach being more effective or cost-effective to usual care, it will provide the evidence to support the status quo and avoid potentially costly and difficult changes in practice.
